The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in nontrial patients in two cancer centers.
Aflah Roohullah
No relevant relationships to disclose
Katrin Marie Sjoquist
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Weng Ng
No relevant relationships to disclose
Wei Chua
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Niall C. Tebbutt
Consultant or Advisory Role - Roche (U)
Lorraine A. Chantrill
No relevant relationships to disclose